Advances in pharmacotherapy for rosacea: what is the current state of the art?

Dall’Oglio, Federica; Nasca, Maria Rita; Gerbino, Carlo; Micali, Giuseppe

doi:10.1080/14656566.2022.2142907

Cited by 7 publications

(4 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many trials not only on TSP and TMP but also on the other topical agents for the treatment of rosacea have been conducted in Western countries (12) . Taieb et al reported that topical 1% ivermectin cream once a day was more effective than TMP (0.75%) twice a day (13) .…”

Section: Discussionmentioning

confidence: 99%

Real-world Evidence for the Treatment of Rosacea with Sulfur or Metronidazole Preparation in Japanese Patients

2023

JMA J

View full text Add to dashboard Cite

Introduction: There remains to be lacking real-world evidence for the treatment of rosacea with a topical sulfur preparation (TSP) or topical metronidazole preparation (TMP) among Japanese patients. Therefore, in this study, we examined the effects of TSP and TMP on rosacea in Japanese patients in real-world clinical settings. Methods: This retrospective observational analysis reviewed the medical records of 47 Japanese patients who were treated with TSP or TMP for more than 8 weeks in our clinic. Disease severity was evaluated using the Investigator Global Assessment (IGA) and the visual analog scale (VAS) for itching, burning sensation, flushing, and hypersensitivity before and 8 weeks after the initiation of the intervention. Results: In total, 10 erythematotelangiectatic rosacea (ETR) and 12 papulopustular rosacea (PPR) patients treated with TSP and 12 ETR and 13 PPR patients treated with TMP were analyzed. IGA and VAS scores for itching, burning sensation, flushing, and hypersensitivity were noted to significantly improve in the ETR and PPR patient groups treated with TSP and both groups treated with TMP, except for the VAS score for itching in the TSP-treated ETR group. No significant differences were observed in terms of the improvement rates of IGA, VAS scores, or the prevalence of adverse events between the TSP- and TMP-treated groups. Conclusions: As per our findings, TSP and TMP have similarly favorable effects on both ETR and PPR in Japanese patients in real-world settings.

show abstract

Section: Discussionmentioning

confidence: 99%

Real-world Evidence for the Treatment of Rosacea with Sulfur or Metronidazole Preparation in Japanese Patients

2023

JMA J

View full text Add to dashboard Cite

show abstract

“…Metronidazole (MTZ) is a nitroimidazole antibiotic approved for papulopustular rosacea [120]. It is available in different formulations (as a gel, cream, or lotion).…”

Section: Papulopustular Rosaceamentioning

confidence: 99%

Advances in the Pathogenesis and Treatment of Rosacea: A Phenotype-Based Therapeutic Approach

Galluccio,

D’Onghia,

Malvaso

et al. 2024

Cosmetics

View full text Add to dashboard Cite

Rosacea is a common chronic inflammatory skin disorder that mainly affects the central face. It is primarily characterized by recurrent episodes of flushing, persistent erythema, inflammatory papules, telangiectasias, phymatous changes, and ocular symptoms. Its pathogenesis is complex and still not completely understood. It encompasses innate and adaptive immune system dysregulation, neurovascular dysfunction, and genetic and environmental factors. To date, four subtypes of rosacea have been identified, based on the predominant clinical features: erythemato-teleangiectatic, papulopustular, pyhomatous, and ocular rosacea. New insights into this condition have led to several pharmacological treatments, including topical medications, spanning from the conventional azelaic acid, metronidazole, benzoyl peroxide, clindamycin, and erythromycin to new ones including not only brimonidine, oxymetazoline, ivermectine, and minocycline but also systemic drugs such as oral antibiotics, isotretinoin, non-selective β-blockers or α2-adrenergic agonists, and laser- or light-based therapies, together with new therapeutic approaches. The aim of this study was to review the current literature on the pathophysiology of rosacea and to provide an overview of therapeutic approaches that specifically address each clinical subtype.

show abstract

“…The patients in this manuscript have given written informed consent to the publication of their case details. Federica Dall'Oglio 1 Maria Rita Nasca 1 Francesco Lacarrubba 1 Pasquale Vitale 1 Helga Platania 1 Beatrice Nardone 2,3 Giuseppe Micali 1…”

Section: E T H Ic S S Tat E M E N Tmentioning

confidence: 99%

“…Dear Editor, Rosacea is a chronic inflammatory skin disease that usually affects the centrofacial areas and rarely the scalp, where papules/pustules may be observed. 1,2 To date, little is known about scalp rosacea due to the limited number of reports. [3][4][5][6][7] In clinical practice, however, quite often rosacea patients report of the occurrence of similar facial inflammatory lesions also on the scalp (authors observation).…”

mentioning

confidence: 99%

Rosacea of the scalp: Results from a retrospective and prospective randomized controlled study

Dall'Oglio,

Nasca,

Lacarrubba

et al. 2024

Acad Dermatol Venereol

Self Cite

View full text Add to dashboard Cite

Advances in pharmacotherapy for rosacea: what is the current state of the art?

Cited by 7 publications

References 63 publications

Real-world Evidence for the Treatment of Rosacea with Sulfur or Metronidazole Preparation in Japanese Patients

Real-world Evidence for the Treatment of Rosacea with Sulfur or Metronidazole Preparation in Japanese Patients

Advances in the Pathogenesis and Treatment of Rosacea: A Phenotype-Based Therapeutic Approach

Rosacea of the scalp: Results from a retrospective and prospective randomized controlled study

Contact Info

Product

Resources

About